Doctiplus - We are allways here!

Mn-Sn: 8am to 9pm

Heart Disease & Cardiovascular — Weekly Report — October 12, 2026

Home/Health Insights/Heart Disease & Cardiovascular — October 12 – October 19, 2026
Vol. 7 · No. 46
DoctiPlus Care · Weekly Brief on Heart Disease & Cardiovascular
Updated Saturday · November 14, 2026
Heart Disease & Cardiovascular · October 12 – October 19, 2026

Heart Disease & Cardiovascular
Weekly Report

This week's data 78 new clinical trials registered across 10 countries, with 8,793 trials actively recruiting patients worldwide.
Week of October 12 – October 19, 2026
  • 78 new clinical trials registered across 10 countries.
  • 8,793 trials actively recruiting patients worldwide.
  • Notable trial: A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Ag... (16390 patients).
  • 2,215 new research papers published.
  • Drug safety: Most reported effect across tracked medications (atorvastatin, lisinopril, metoprolol, amlodipine, warfarin) was Fatigue.
  • No active drug recalls for tracked medications this week.

The week in numbers

Figures · October 12 – October 19, 2026
New Trials This Week
78.
registered Oct 12–Oct 19
Recruiting Now
8,793
active trials seeking patients
Countries
10
with active trials this week
Papers Published
2,215
new studies this week
Phase 3 Trials
3
late-stage trials this week
Fig. 01

Trials by country

Count · October 12 – October 19, 2026
Poland
8
Not specified
7
United States
7
Denmark
7
China
4
Norway
4
South Korea
4
Spain
4
Turkey (Türkiye)
4
Japan
4
0 2 4 6 8
total
Fig. 02

Trials by phase

Distribution · October 12 – October 19, 2026

New clinical trials registered this week for Heart Disease & Cardiovascular. Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.

§ 03

This week's new registrations

Click any header to sort

78 trials registered for Heart Disease & Cardiovascular. Each links to its full record on ClinicalTrials.gov.

# Trial ↓ Phase ↕ Status ↕ Enrollment ↕ Country ↕
01 IMPROVE-STEMI: pPCI Plus Low-dose r-SK in STEMI Heart Disease & Cardiovascular · The Affiliated Hospital of Xuzhou Medical University (NCT07875179) Phase 4 Not Yet Recruiting 3,300 China
02 Multimodality Assessment of Myocardial Reperfusion After Primary Percutaneous Coronary Intervention Heart Disease & Cardiovascular · Assiut University (NCT07876791) Other Not Yet Recruiting 90 N/A
03 Carotid Plaque RADS vs CPVH: Diagnostic Accuracy Comparison Heart Disease & Cardiovascular · Limited Liability Company "European Institute of Family Health" (NCT07870512) Other Completed 150 Russia
04 HRV Variation in Rheumatoid Arthritis Heart Disease & Cardiovascular · University of Central Florida (NCT07878975) Other Recruiting 30 United States
05 Acute Effects of Mat Pilates on Blood Pressure Response to Mental Stress in Higher Education Teachers Heart Disease & Cardiovascular · Federal University of Mato Grosso (NCT07872592) Other Not Yet Recruiting 25 Brazil
06 Ligasure Versus Conventional Diathermy in Hemorrhoidectomy Heart Disease & Cardiovascular · Sohag University (NCT07878546) Other Recruiting 40 Egypt
07 Double Transseptal Guide Sheath to Prevent Dock Drop During SAPIEN M3 Transcatheter Mitral Valve Replacement Heart Disease & Cardiovascular · Medical University of Vienna (NCT07878195) Other Completed 77 Austria
08 Cardiovascular Risk in Patients With Primary Hyperparathyroidism Heart Disease & Cardiovascular · Medical University of Sofia (NCT07870369) Other Completed 77 Bulgaria
09 Infarct Growth After Intravenous Tocilizumab in Adults With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy - ILLUMINATE Heart Disease & Cardiovascular · Oslo University Hospital (NCT07870681) Phase 3 Not Yet Recruiting 156 Denmark
10 Predicting High-Risk Carotid Plaque: Integrating radioMics and biomEchanics Heart Disease & Cardiovascular · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (NCT07877480) Other Recruiting 420 Italy
11 A Study on the Impact of Recombinant Zoster Vaccine on Major Adverse Cardiovascular Events in Adults >=50 Years of Age With Established Cardiovascular Disease or With >=2 Cardiovascular Risk Factors Heart Disease & Cardiovascular · GlaxoSmithKline (NCT07872046) Phase 3 Not Yet Recruiting 16,390 N/A
12 A Real World Evidence Retrospective Data Collection Study of Edoxaban and Rivaroxaban Heart Disease & Cardiovascular · Daiichi Sankyo (NCT07874555) Other Completed 8,265 South Korea
13 Hypermobile Ehlers Danlos Syndrome Healthcare Usage and Outcomes in England Heart Disease & Cardiovascular · Walton Centre NHS Foundation Trust (NCT07878793) Other Withdrawn 0 N/A
14 The Metabolic Response of Unweighted Treadmill Walking Heart Disease & Cardiovascular · NYU Langone Health (NCT07870434) Other Completed 25 United States
15 Additional Effects of Flutter With Conventional Chest Physiotherapy on Peak Expiratory Flow Rate and Chest Expansion in Post CABG Patients With COPD Heart Disease & Cardiovascular · Foundation University Islamabad (NCT07875049) Other Recruiting 84 Pakistan
16 Real-World Outcomes of Drug-Coated Balloon Angioplasty in Coronary Artery Disease Heart Disease & Cardiovascular · Kristian Rivera (NCT07875088) Other Not Yet Recruiting 2,000 Mexico
17 MSC Secretome and rTMS for Motor Recovery After Subacute Ischemic Stroke Heart Disease & Cardiovascular · Jumraini Tammasse (NCT07874269) Other Not Yet Recruiting 205 Indonesia
18 Vascular Inflammation in Atherosclerosis - Whole Body Molecular PET/CT Imaging Using Folate Receptor β Heart Disease & Cardiovascular · Turku University Hospital (NCT07877324) Other Recruiting 90 Finland
19 Decompressive Craniectomy After Aneurysmal Subarachnoid Hemorrhage (DECIDE-SAH) Heart Disease & Cardiovascular · University Hospital, Essen (NCT07872774) Other Not Yet Recruiting 10,000 Germany
20 Sevoflurane Versus Propofol Anesthesia in Intracardiac Echocardiography-Guided Atrial Fibrillation Ablation Heart Disease & Cardiovascular · Hüseyin Ulaş Pinar (NCT07877116) Phase 4 Not Yet Recruiting 124 Turkey (Türkiye)
21 Integrated Near-Infrared Spectroscopy and Hemodynamic Monitoring for Cerebral Autoregulation in Post-Cardiac Arrest Care Neuroprognostication Heart Disease & Cardiovascular · National Taiwan University Hospital (NCT07875348) Other Not Yet Recruiting 60 Taiwan
22 Dynamic Arterial Elastance for Prediction of Vasopressor Requirement After Anesthesia Induction in Elective On-Pump CABG Heart Disease & Cardiovascular · Elzem SEN (NCT07871201) Other Recruiting 42 Turkey (Türkiye)
23 Association Between Intraoperative Pulse Pressure Variation and Postoperative Lactate Clearance in Cardiac Surgery Heart Disease & Cardiovascular · Elzem SEN (NCT07871188) Other Recruiting 100 Turkey (Türkiye)
24 Antihypertensive Self-titration in US Primary Care Heart Disease & Cardiovascular · Brigham and Women's Hospital (NCT07869966) Other Not Yet Recruiting 30 United States
25 TOP-CABG Trial: Follow-up Extension (TOP-CABG FE) Heart Disease & Cardiovascular · China National Center for Cardiovascular Diseases (NCT07871591) Other Not Yet Recruiting 2,290 N/A
26 A Study on Abnormal Menstrual Bleeding in Chinese Women of Childbearing Age Taking Antithrombotic Drugs After Cardiovascular Surgery Heart Disease & Cardiovascular · Shanghai Zhongshan Hospital (NCT07870941) Other Recruiting 1,308 China
27 Text Message Support to Help Adults With Newly Diagnosed High Blood Pressure Control Their Blood Pressure in Primary Care Clinics in Germany and Pakistan Heart Disease & Cardiovascular · GIFT University (NCT07878728) Other Completed 1,295 Pakistan
28 Healing Hearts: A Mindfulness App for Parents Navigating Divorce or Separation Heart Disease & Cardiovascular · University of Connecticut (NCT07871916) Other Recruiting 96 United States
29 Cardiocentric Inotropic Optimization in Spinal Cord Injury Heart Disease & Cardiovascular · University of British Columbia (NCT07871643) Phase 1 Not Yet Recruiting 8 Canada
30 Premature Ventricular Complex and Diet Inflamatuar Index Heart Disease & Cardiovascular · Izmir Democracy University (NCT07870109) Other Not Yet Recruiting 100 Turkey (Türkiye)
31 Investigating Techniques to Enhance the Sense of Embodiment in Immersive Virtual Reality Heart Disease & Cardiovascular · IRCCS Eugenio Medea (NCT07870044) Other Recruiting 90 Italy
32 Effectiveness of the "Aktivplan" Digital Intervention for Supporting Regular Heart-Healthy Physical Activity Following Phase II Cardiac Rehabilitation Heart Disease & Cardiovascular · Salzburg Research Forschungsgesellschaft mbH (NCT07878520) Other Not Yet Recruiting 68 Austria
33 Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets Heart Disease & Cardiovascular · Humanis Saglık Anonim Sirketi (NCT07872358) Phase 1 Completed 36 India
34 Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder Heart Disease & Cardiovascular · Clive Michelsen (NCT07871877) Phase 2 Not Yet Recruiting 60 United States
35 Feasibility of Combination Therapy With Low-dose Statin and Ezetimibe in Patients With Minimal Subclinical Atherosclerosis Heart Disease & Cardiovascular · Yonsei University (NCT07871604) Phase 4 Not Yet Recruiting 300 South Korea
36 Innovative Approaches to Identify Causative Genetic Variants in Patients With Unexplained Bleeding Disorders Heart Disease & Cardiovascular · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (NCT07870057) Other Completed 122 Italy
37 Comparative Study of Combination Treatment of Bionerv E+ Versus Vitamin B Complex in Treatment of Diabetic Polyneuropathy in Type 2 Diabetic Patients and Its Effect on Wound Healing Heart Disease & Cardiovascular · BREGO Life Sciences (NCT07877948) Other Recruiting 100 Malaysia
38 Head-to-Head (H2H) Comparison of Ambulatory Cardiac ECG Monitors in Japan Heart Disease & Cardiovascular · iRhythm Technologies, Inc. (NCT07870837) Other Not Yet Recruiting 130 Japan
39 Enabling Bedside Brain Measurement of Motor Outcomes Post Stroke Heart Disease & Cardiovascular · Sue Peters (NCT07876700) Other Not Yet Recruiting 60 N/A
40 1-Month Versus 6-Month Dual Antiplatelet Therapy After Successful Drug-Coated Balloon-Only Percutaneous Coronary Intervention Heart Disease & Cardiovascular · Ulsan University Hospital (NCT07879430) Other Not Yet Recruiting 1,258 N/A
41 Serratus Anterior Plane Block for Recovery After Minimally Invasive CABG Heart Disease & Cardiovascular · Chinese PLA General Hospital (NCT07877532) Other Not Yet Recruiting 168 N/A
42 Bachmann's Bundle Versus Right Atrial Appendage Pacing Heart Disease & Cardiovascular · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) (NCT07874763) Other Recruiting 334 United States
43 Sitogilun Malate Plus Amlodipine in Patients With Hypertension and Risk of Early Kidney Damage Heart Disease & Cardiovascular · Shanghai Jiao Tong University School of Medicine (NCT07876544) Phase 4 Recruiting 456 China
44 Vortosiran in Atrial Fibrillation Heart Disease & Cardiovascular · Ribocure Pharmaceuticals AB (NCT07870889) Phase 2 Not Yet Recruiting 150 Denmark
45 Monitoring the Effectiveness and Safety of Antihypertensive Therapy With a Fixed-Dose Combination of Perindopril and Amlodipine in Patients With Uncontrolled Essential Hypertension Heart Disease & Cardiovascular · Bosnalijek D.D (NCT07876895) Other Active Not Recruiting 600 Bosnia and Herzegovina
46 Anticoagulant Cessation After Antiphospholipid Autoantibodies Loss in Thrombotic Antiphospholipid Syndrome Heart Disease & Cardiovascular · Assistance Publique - Hôpitaux de Paris (NCT07875153) Phase 3 Not Yet Recruiting 234 France
47 Vericiguat Use and Incident Atrial Fibrillation in Chronic Heart Failure Heart Disease & Cardiovascular · Beijing Tsinghua Chang Gung Hospital (NCT07877831) Other Active Not Recruiting 918 China
48 Effects of a Specialized Diabetes and Heart Clinic and Detection of Unrecognized Heart Failure in People With Type 2 Diabetes and Cardiovascular Disease Heart Disease & Cardiovascular · Odense University Hospital (NCT07878325) Other Recruiting 375 Denmark
49 Pilot Study: Evaluation of the Safety of the Application of Non-thermal HIFU for Varicose Veins Treatment of the Lower Limbs Heart Disease & Cardiovascular · VeinSound (NCT07878767) Other Recruiting 15 Romania
50 Brain and Heart Rhythm Responses to a Breathing-Linked Sound Application (BELL-001) in Adults With Insomnia Symptoms Heart Disease & Cardiovascular · BELL Therapeutics Inc. (NCT07872007) Other Completed 72 South Korea
§ 04

Adverse event reports

FDA FAERS · 2025 data

Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Heart Disease & Cardiovascular. These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.

Reports by drug

DrugTop effectCount
atorvastatin Fatigue 1,084
lisinopril Fatigue 1,493
metoprolol Fatigue 1,783
amlodipine Fatigue 2,132
warfarin Off Label Use 239

Recalls & safety notices

§ 05 · 0 items this week

FDA drug recall notices for medications related to Heart Disease & Cardiovascular. If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.

No active drug recalls for tracked medications this period.

§ 06

Published research

2,215 papers

Recently published peer-reviewed studies related to Heart Disease & Cardiovascular, sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.

# Study Journal Date Source
01 Occupational noise exposure and ischemic heart disease: a pooled analysis of six Nordic cohorts. Lissåker C et al. 10.5271/sjweh.4333
View abstract

OBJECTIVES: This study aimed to investigate the impact of occupational noise exposure on incident ischemic heart disease (IHD), including acute myocardial infarction (AMI). METHODS: We conducted a pooled analysis of six Nordic cohorts with a total of 83 103 participants with individual and area-level confounder information. Occupational codes were matched to a job-exposure matrix developed from Swedish measurements in five categories (LAeq8h): <70, 70-74, 75-79, 80-84, and ≥85 dB(A). Residential address history was used to estimate baseline 1-year average residential road traffic noise exposure. Data on incident IHD and AMI were obtained from national patient registers. We calculated hazard ratios (HR) using Cox proportional hazard models adjusted for socioeconomic and lifestyle factors. RESULTS: After adjustment for baseline year, sex, marital status, area-level income, education, smoking, and physical activity, exposure to ≥85 dB(A) of occupational noise was associated with an 10% and 12% increased risk of IHD, excluding angina pectoris, and AMI, respectively. For these outcomes, suggestive exposure-response trends were observed, but risks were only statistically significant for those exposed to ≥85 dB(A) as well as men exposed to ≥75 dB(A). We did not find evidence that combined exposure to both occupational noise and road traffic noise was particularly harmful. CONCLUSION: We found increased risks of IHD and AMI among those exposed to occupational noise ≥85 dB(A). Further studies should investigate whether this association is confounded by other occupational exposures.

Scandinavian journal of work, environment & health 2026 Oct 18 PubMed
02 Acinar-Derived Organoids Reveal Stage-Specific Control of Acinar Plasticity. Hou Y et al. 10.1002/advs.78350
View abstract

Adult pancreatic acinar cells undergo ordered metaplastic conversion during injury and tumor initiation. Whether individual cells retain redifferentiation capacity after metaplastic expansion, and what signals each transition requires, remains unknown. Here, using organoids derived from single acinar cells, we show that expanded acinar-lineage organoids can reacquire acinar features under stage-specific culture conditions. We defined conditions that preserve acinar identity ex vivo and showed that epidermal growth factor (EGF)/EGF receptor (EGFR) signaling initiates conversion from this maintained state. The expansion trajectory recapitulates injury- and oncogene-associated acinar-to-ductal metaplasia (ADM) programs in vivo. After expansion, the conditions that preserved acinar identity could not restore it; a staged regimen containing transient insulin-like growth factor 1 receptor (IGF1R) inhibition and dexamethasone promoted redifferentiation. The Kras;Trp53;Pdx1-Cre (KPC) genotype reduced EGFR dependence during initiation but destabilized post-expansion redifferentiation; Kras-pathway inhibition increased endpoint acinar-marker expression. These findings demonstrate that acinar plasticity is organized by stage-specific signals, and that the KPC genotype disrupts this control at specific transition points.

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026 Oct 18 PubMed
03 Symptom-Driven Prediction of Chronic Multimorbidity with a Macro-Micro Heterogeneous Graph Neural Network. Ye Y et al. 10.1002/advs.78348
View abstract

The growing prevalence and complexity of multimorbidity pose significant challenges to healthcare systems worldwide. Here, we developed a heterogeneous graph neural network framework for multilabel multimorbidity prediction. The framework jointly encodes symptom and diagnostic information within a heterogeneous graph and incorporates biomedical knowledge subgraphs on both the disease and symptom sides. By integrating macro-level clinical representations of symptoms and diseases with micro-level molecular knowledge, the model generates multilabel probabilities across candidate disease categories. We evaluated the framework in two complementary tasks: Patient-Level Symptom-Disease Association (Task 1) and Visit-Level Multimorbidity Completion (Task 2). In Task 1, symptoms recorded across all eligible visits within each patient's observation window were aggregated into a patient-level symptom set to predict the disease categories recorded for that patient within the same observation window. In Task 2, symptoms and a subset of recorded positive diagnoses from the same visit were used to predict the remaining disease categories recorded for that visit. Together, these two tasks provide a unified framework for patient-level symptom-disease association and visit-level multimorbidity completion. The framework characterized symptom-disease-biomedical knowledge associations and non-random patterns of disease co-occurrence, while supporting both patient-level symptom-disease association and visit-level multimorbidity completion.

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026 Oct 18 PubMed
04 Magnetic resonance imaging vs computed tomography for baseline imaging evaluation in acute basilar artery occlusion. Gao F et al. 10.1007/s00415-026-14159-4
View abstract

BACKGROUND: The optimal imaging modality, magnetic resonance imaging (MRI) or computed tomography (CT), for identifying good treatment candidates among patients with acute basilar-artery occlusion (BAO) remains unclear. METHODS: This was a post hoc analysis of the ATTENTION trial. Patients were categorized into MRI or CT groups according to the baseline imaging modality. The primary outcome was mRS 0-3 at 90 days. The secondary outcomes included mRS score shift on an ordinal scale, early neurological deterioration, time from stroke onset to arterial puncture, and time from onset to randomization. The safety outcome was mortality within 90 days. Clinical outcomes and workflow times were compared between the two groups. RESULTS: Among 340 patients (CT: n = 277; MRI: n = 63), baseline imaging was not significantly associated with 90-day mRS 0-3 in the overall cohort (OR 0.99, 95% CI 0.50-1.95; P = 0.976). It remained highly consistent across both the endovascular treatment and best medical management subgroups. Baseline MRI assessment was not associated with significant workflow delays compared with CT, including time from stroke onset to randomization (mean difference [MD] 5.23 min; P = 0.843) and time to puncture (MD 13.16 min; P = 0.701). Furthermore, the association between imaging modality and outcomes was consistent across different time windows. DISCUSSION: In patients with acute BAO, we did not observe evidence supporting the preferential use of MRI over CT as the primary imaging strategy for patient selection. Conventional imaging appears sufficient as a first-line tool for selecting patients in clinical practice.

Journal of neurology 2026 Oct 18 PubMed
05 Indirect Echocardiographic Signs of Increased Right-sided Afterload in Progressive Pulmonary Fibrosis: Insights from a Multicentre Italian Study. Cefalo J et al. 10.1007/s00408-026-00955-2
View abstract

PURPOSE: Pulmonary vascular involvement is a determinant of worse outcomes in fibrotic lung diseases. Its prevalence and prognostic relevance in patients with progressive pulmonary fibrosis (PPF) is unknown. The aim of this study was to assess the prevalence of indirect echocardiographic abnormalities in progressive pulmonary fibrosis before antifibrotic therapy, characterize a baseline high-risk cardiopulmonary functional profile, and assess 12-month clinical trajectories. METHODS: Observational, retrospective, multicentre study. RESULTS: 158 patients (median (IQR) age of 71 (65.2-77.0) years) with PPF were enrolled. Thirty (19.0%) had ≥ 1 echocardiographic indirect sign of increased right-sided afterload, 15 (9.5%) ≥ 2, 9 (5.7%) ≥ 3 and 1 (0.6%) all four. A shortened right ventricular outflow tract acceleration time (< 105 ms) was the most frequent alteration (12.7%), followed by right atrial dilation (10.8%). In univariable analysis, ≥1 sign was associated with male sex, a lower DLCO% predicted, a higher FVC%/DLCO% ratio and a shorter 6MWD; in the multivariable model only, male sex remained independently associated (aOR 3.45, 95% CI 0.99-12.07; p = 0.052). Twelve-month FVC trajectories did not differ by baseline echocardiographic status; nonetheless, ≥1 sign was associated with shorter time to acute exacerbation (log-rank p = 0.007) and all-cause hospitalisation (p = 0.001). CONCLUSIONS: Echocardiographic signs suggestive of increased right-sided afterload are present in a substantial proportion of PPF patients at the time of antifibrotic initiation. They identified patients at higher risk of acute exacerbation and hospitalisation, regardless of FVC decline. This higher-risk subgroup warrants specific pulmonary vascular evaluation and tighter clinical follow-up.

Lung 2026 Oct 18 PubMed
06 A Micropeptide Component of the OGDH Complex Modulates ATP Production in the TCA Cycle. Yin X et al. 10.1002/advs.77242
View abstract

Since its elucidation, the tricarboxylic acid (TCA) cycle has been regarded as a fully defined enzymatic pathway. Here, we report the discovery of a previously unrecognized micropeptide component of this central metabolic system. Through analyzing ribosome profiling data from the mouse sORFs.org database, we discovered APPM (ATP production-promoting micropeptide), a 29-amino acid peptide encoded by a non-canonical small open reading frame within the mouse Ctsb gene. APPM localizes to the mitochondrial matrix and inner membrane, where it directly binds to the E1 subunit (OGDH) of the α-ketoglutarate dehydrogenase complex (OGDHc). This interaction modulates OGDHc enzymatic activity, thereby regulating NADH and ATP production. We identified tyrosine-13 as the critical residue mediating the APPM-OGDH interaction and functional activation. Exogenous APPM administration increased ATP levels in vivo and, in a mouse model of heart failure, restored cardiac function, outperforming the reference drug trimetazidine. Collectively, our findings identify APPM as the first micropeptide regulator of the OGDH complex, expanding the known repertoire of the TCA cycle and presenting a potential therapeutic strategy for diseases characterized by bioenergetic insufficiency.

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026 Oct 18 PubMed
07 How relationships with exercise change: A qualitative study on the influences of exercise decision-making with systemic lupus erythematosus and cardiovascular disease. Frederick MJ et al. 10.1177/09612033261499215
View abstract

Greater than 50% of individuals with systemic lupus erythematosus (SLE) will develop cardiovascular disease (CVD). Moderate-intensity aerobic exercise significantly reduces CVD risk, morbidity, and mortality, yet most persons with SLE do not meet the minimum recommendations for physical activity. To explore specific barriers to exercise that afflict those with both SLE and CVD, as well as how these factors may change over time. Qualitative. Individuals with self-reported SLE and CVD. Researchers conducted 1:1 semi-structured interviews and administered a battery of surveys. Analysis. Researchers used an inductive, interpretive phenomenological analysis qualitative approach to understand patients' perspectives on what influences perception and decision-making of exercise. Five participants completed the study. Four overarching themes were identified. The first, "Short-term Risks versus Long-term Benefits of Exercise," exemplifies the temporal nature of the perception of exercise risk throughout the diagnostic timeline and explains how this relationship changes over time. The second, "Pacing," defines the struggle that these participants face when allocating energy to everyday tasks. The third, "Foundational and Nurturing Supports for Exercise," describes the impact that medical and family/friends have on exercise adherence as primary methods of support. The fourth highlights a "Need for Tailored Intervention" for each patient with SLE and CVD, as general recommendations from health professionals are often described as difficult to adhere to. Understanding exercise adherence in this population represents a dynamic and individualized process. The success of long-term decisions to engage in exercise may result from targeting natural intervention areas across the diagnostic timeline, encouraging support from healthcare providers, friends, and family members, and implementing personalized exercise programs for this population.

Lupus 2026 Oct 18 PubMed
08 Cardiology Support Utilization Patterns and Associated Barriers Across Northwestern Ontario. Al-Atawneh J et al. 10.1177/08404704261492943
View abstract

The Thunder Bay Regional Health Sciences Centre On-Call Cardiology Support Service serves a geographically vast region across Northwestern Ontario where cardiovascular disease is a major burden. The objective is to analyze service utilization patterns including locations, indications, interventions, and barriers. In this 6-month prospective study, cardiologists collected data via survey on calls from rural and remote providers. Descriptive statistics and Fisher's exact test were used. The Canadian Institute for Health Information's Rural Health Systems Model was used for interpretation. Two hundred and six responses across 19 locations identified: common consultations-chest pain, dyspnea, and atrial fibrillation; frequent interventions-medical recommendations, education, and transfer decisions; key barriers-limited personnel knowledge and infrastructure. Significant associations were identified. This study characterized cardiology support service utilization across Northwestern Ontario, identifying key barriers and opportunities to strengthen rural health systems planning and cardiovascular care. These findings can inform targeted initiatives and support future evaluations.

Healthcare management forum 2026 Oct 18 PubMed
09 The "living well with lupus" lifestyle intervention: Effects on gut microbiota in patients with systemic lupus erythematosus and high cardiovascular risk. Romero MA et al. 10.1177/09612033261496128
View abstract

BackgroundSystemic lupus erythematosus (SLE) is an autoimmune disease associated with increased cardiovascular risk and gut microbiota dysbiosis. Although lifestyle can modulate the microbiome, the impact of multidisciplinary interventions in SLE remains unclear. Thus, the aim of the present study was to investigate the effects of a multidisciplinary lifestyle intervention on gut microbiota diversity and composition in women with SLE and high cardiovascular risk.Materials and methodsThis study analyzed a subsample ( = 31) from the "Living Well with Lupus" (LWWL) study, a 6-month randomized controlled trial. Patients were assigned to a lifestyle intervention + standard care (LWWL) or a standard care control group (CG). Gut microbiota (16S rRNA sequencing), fecal short-chainfatty acids (SCFAs), selected cardiovascular risk factors, dietary intake, and physical activity levels were assessed before and after the intervention.ResultsNo significant changes were observed in cardiovascular risk factors, food intake, or physical activity levels. Fecal SCFA concentrations and alpha/beta diversity also remained stable. Exploratory taxonomic analyses nevertheless identified distinct relative-abundance patterns across groups and time, including a numerical increase in the -to- (F/B) ratio in LWWL and different trajectories of several SCFA-associated genera. Among these, and increased, whereas , , and decreased from pre- to post-intervention in LWWL, with different trajectories observed in CG across these genera.ConclusionsThese findings suggest that taxonomic features of the gut microbiota may show compositional variation following a lifestyle intervention even in the absence of detectable changes in the measured cardiometabolic or behavioral outcomes. However, the functional and clinical significance of these exploratory taxonomic patterns remains uncertain and warrants further investigation.

Lupus 2026 Oct 18 PubMed
10 Patterns of cardiovascular disease subtypes and associated factors among young adults in Peshawar, Pakistan: a multicenter hospital-based cross-sectional study. Arif N et al. 10.1080/14796678.2026.2739742
View abstract

BACKGROUND: Cardiovascular diseases (CVDs) are a major cause of morbidity and mortality. Evidence on CVD subtypes in young Pakistani adults is limited. This study characterized CVD subtypes and associated factors among young adults in Peshawar Khyber Pakhtunkhwa, Pakistan. METHODS: A multicentre, cross-sectional study was conducted at four hospitals among patients aged 18-45 years. Data were extracted from three-year hospital records. Associations were assessed using chi-square/Fisher's exact tests and logistic regression. RESULTS: 8,650 CVD cases, 2,090 (24.2%) were young adults, predominantly male (64.6%), with a median age of 40 years (IQR: 36-44). ACS was the most common subtype (61.0%), followed by cardiomyopathy (39.0%). Overweight/obesity (77.0%), hypertension (56.5%), smoking (39.7%), dyslipidaemia (21.8%), and diabetes (14.4%) were the most prevalent factors. Compared with ACS, cardiomyopathy was independently associated with high heart rate, hypertension, dyslipidaemia, diabetes, and family history. Smoking was associated with lower odds of cardiomyopathy than ACS (aOR: 0.50, 95% CI: 0.41-0.61,  < 0.001). CONCLUSIONS: Young adults accounted for 24.2% of CVD cases, with ACS and cardiomyopathy the most common subtypes, highlighting the need for targeted strategies. The cross-sectional design, findings indicate subtype differences rather than causal effects, while supporting smoking cessation and early hypertension detection in young adults.

Future cardiology 2026 Oct 18 PubMed
11 Prediction of acute mountain sickness risk by pre-plateau uric acid and albumin levels in Chinese young males: a prospective cohort study. Xie HC et al. 10.7717/peerj.21770
View abstract

OBJECTIVE: To screen and identify pre-plateau hematological parameters that can predict the risk of acute mountain sickness (AMS) in individuals rapidly ascending to high altitudes. METHODS: A total of 297 healthy adult males with an average age of 20.88 ± 1.76 years were included in the study. Baseline data were collected at an altitude of 300 m using questionnaire surveys, on-site testing, and hematological parameter tests (including routine blood and serum biochemical parameters with validated clinical detection systems). After ascending to an altitude of 4,200 m, the Lake Louise Score (LLS) 2018 and physiological indicator measurements were obtained on the second day. AMS was defined as an LLS 2018 ≥3 points accompanied by headache. A univariate logistic regression model was used to screen for the hematological parameters associated with AMS. Multivariate logistic regression was then used to adjust for covariates and determine the relationship between pre-plateau albumin (ALB) levels, uric acid (UA) levels, UA-to-ALB ratio (UAR), and AMS risk. Additionally, the predictive value was assessed using the receiver operating characteristic (ROC) curve, and the optimal cutoff value was determined using the Youden index. Finally, a subgroup analysis was conducted to determine the consistency of associations. RESULTS: The incidence of AMS after arriving at the 4,200 m plateau was 29.97%. Univariate logistic regression analysis revealed associations between factors at 300 m, including heart rate, alcohol consumption, ALB, UA, and AMS. In the fully adjusted multivariate Model 3, pre-plateau ALB, UA, and UAR showed moderate predictive performance for AMS, with area under the ROC curve values of 0.710, 0.701, and 0.711, respectively (all < 0.001). The optimal cutoff values were 47.25 g/L for ALB, 420.10 μmol/L for UA, and 7.45 for UAR. The UAR exhibited favorable predictive performance in populations with a body mass index <25 kg/m, a history of low-altitude residence, or alcohol consumption. CONCLUSION: Pre-plateau UA levels, ALB levels, and UAR are independent predictors of AMS risk in young healthy Chinese males. All three biomarkers exhibited moderate predictive performance, with the UAR showed particular utility in specific subgroups.

PeerJ 2026 PubMed
12 Baseline Serum HMGB1 and the Composite of All-Cause Mortality or First Heart Failure Rehospitalization in Heart Failure with Preserved Ejection Fraction. Chen H et al. 10.2147/JIR.S633336
View abstract

PURPOSE: To evaluate the association between baseline serum high mobility group box 1 (HMGB1) and the composite of all-cause mortality or first heart failure rehospitalization in patients with heart failure with preserved ejection fraction (HFpEF). PATIENTS AND METHODS: This single-center prospective cohort included 224 patients with HFpEF. The primary endpoint was the first occurrence of all-cause mortality or heart failure rehospitalization. RESULTS: During a median observation time of 58 months, 37 of 224 patients (16.5%) experienced the composite endpoint. Baseline HMGB1 was higher in patients with events than in those without events (8.76 ± 3.18 vs 5.99 ± 1.86 µg/L; P<0.001). After adjustment for NT-proBNP, age, and sex, each 1 µg/L increase in HMGB1 was associated with a higher risk of the composite endpoint (hazard ratio, 1.399; 95% confidence interval [CI], 1.242-1.576; P<0.001). Apparent areas under the curve were 0.753 (95% CI, 0.653-0.853) for HMGB1, 0.790 (95% CI, 0.708-0.872) for NT-proBNP, and 0.870 (95% CI, 0.793-0.947) for their combination. The combination did not significantly outperform NT-proBNP alone (ΔAUC, 0.080; 95% CI, -0.012 to 0.171; nominal P=0.088; Holm-adjusted P=0.176). The optimism-corrected Cox concordance index was 0.828, and sensitivity analyses showed associations in the same direction. CONCLUSION: Higher baseline serum HMGB1 was associated with the composite of all-cause mortality or first heart failure rehospitalization in this exploratory HFpEF cohort. Incremental discrimination beyond NT-proBNP and clinical utility remain unestablished. Independent prospective multicenter validation is required.

Journal of inflammation research 2026 PubMed
13 Age-Period-Cohort Analysis of the Global Death Burden of Main Diseases Attributable to High Temperature in the Past 30 Years: Based on the Global Burden of Disease Study 2021. Wang Z et al. 10.1029/2025GH001623
View abstract

High temperatures pose a serious threat to human health. Quantifying the main disease death burden attributable to high temperatures can provide scientific evidence for policy development. Using Global Burden of Disease 2021 data, we identified the death burden attributable to high temperatures across all causes and determined the three leading causes. For each, we used age-standardized mortality rates attributable to high temperature (HA-ASMR) and estimated temporal trends via age-period-cohort modeling at global, regional, and national levels (1990-2021). Ischemic heart disease, stroke, and lower respiratory infections were the top three causes of deaths attributable to high temperature in 2021. Low-middle Socio-demographic Index (SDI) regions had the highest HA-ASMR for ischemic heart disease (3.49, 95%UI: 0.96-6.57) and stroke (2.55, 95%UI: 0.77-5.01), whereas lower respiratory infections showed the highest HA-ASMR in low SDI regions (2.52, 95%UI: 0.85-4.35). Age-period-cohort analysis generated net drift values for HA-ASMR in high SDI regions, with values of 0.99% (95%CI: 0.60%-1.39%) for ischemic heart disease, 1.19% (95%CI: 0.99%-1.40%) for stroke, and 2.36% (95%CI: 2.01%-2.70%) for lower respiratory infections. Longitudinal age curves showed elevated mortality risks attributable to high temperature in populations over 60 years. Global period and cohort rate ratios for high-temperature-attributable ischemic heart disease mortality increased over time. Global ischemic heart disease and stroke deaths attributable to high temperature continued rising with sharply elevated risks in older adults, while lower respiratory infection deaths attributable to high temperature among youth in high-income countries are increasing. Therefore, adaptation strategies must be specific to disease and age, varying by regional characteristics.

GeoHealth 2026 Oct PubMed
14 Inverse Association of the Life's Crucial 9 Score With MAFLD: An Exploratory Mediation Analysis of the C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index. Li H et al. 10.1155/ije/1340865
View abstract

BACKGROUND: Metabolic dysfunction-associated fatty liver disease (MAFLD) is strongly associated with cardiovascular disease. Life's Crucial 9 (LC9), an expanded cardiovascular health metric incorporating psychological health, may provide a multidimensional measure of cardiometabolic health. The CALLY index integrates inflammatory, immune, and nutritional information and has been associated with MAFLD. However, whether ln(CALLY) statistically accounts for part of the association between LC9 and MAFLD remains unclear. This study aimed to examine the association between LC9 and MAFLD and to explore the statistical indirect association through ln(CALLY). METHODS: Data were obtained from the National Health and Nutrition Examination Survey (NHANES) conducted between 2005 and 2016. Weighted logistic regression, restricted cubic spline (RCS) modeling, subgroup analysis, and weighted quantile sum (WQS) regression were used to assess the relationship between LC9 and MAFLD. Exploratory mediation analysis was performed to evaluate the statistical indirect association through ln(CALLY). Sensitivity and supplementary analyses were conducted to assess the robustness of the findings with respect to missing data, alternative disease definitions, definitional overlap, alternative cardiovascular health metrics, individual LC9 components, and mediator choice. RESULTS: This study included 3841 participants. Higher LC9 scores were significantly associated with lower odds of prevalent MAFLD. Specifically, every 10-point increase in the LC9 score was associated with lower odds of MAFLD (OR = 0.51, 95% CI: 0.47-0.56, < 0.001). Participants in the highest tertile of the LC9 score had lower odds of MAFLD (OR = 0.16, 95% CI: 0.12-0.22, < 0.001) compared with those in the lowest tertile. Similarly, ln(CALLY) was inversely associated with MAFLD (OR = 0.57, 95% CI: 0.52-0.64, < 0.001). Exploratory mediation analysis indicated that ln(CALLY) statistically accounted for approximately 17.7% of the LC9-MAFLD association ( < 0.001). Sensitivity and supplementary analyses showed that the association was attenuated but remained statistically significant after exclusion of overlapping metabolic components from LC9 (OR per 10-point increase in modified LC9 = 0.891, 95% CI: 0.832-0.955, = 0.002) and remained materially consistent when MASLD was used as an alternative outcome (OR = 0.545, 95% CI: 0.494-0.602, < 0.001). No significant indirect association was observed using PNI as an alternative mediator ( = 0.988). WQS analysis assigned relatively larger weights to BMI, blood glucose, and psychological health. CONCLUSION: Higher LC9 scores were associated with lower odds of prevalent MAFLD. Exploratory mediation analysis suggested a statistical indirect association through ln(CALLY), although causal or temporal mediation cannot be inferred. Further prospective studies are needed to confirm these findings.

International journal of endocrinology 2026 PubMed
15 Insights Into RP2-Associated Retinopathy: From Molecular Basis to Clinical Translation. Bögershausen N et al. 10.1155/humu/1839164
View abstract

Pathogenic variants in cause X-linked -associated retinopathy, a rare inherited retinal disorder typically characterized by childhood onset and progression to severe visual impairment within the first three decades of life. Despite its clinical severity, comprehensive clinical and genetic data on -associated retinopathy remain limited and no therapeutic approaches have yet progressed toward clinical application. Here, we provide an overview of current molecular, clinical, and therapeutic knowledge on -associated retinopathy together with an analysis of the spectrum and distribution of clinically classified, ClinVar-curated variants. Analysis of 325 ACMG/AMP Class 3-5 variants revealed that among pathogenic and likely pathogenic variants, frameshift and nonsense variants predominated, supporting loss of RP2 function as the major disease mechanism as previously described. In contrast, variants of uncertain significance were largely missense variants, underscoring the particular challenge of missense variant interpretation in RP2. Exon distribution of variants did not deviate from expectation for Class 3 variants, or for Class 4 and 5 variants in exons 2-4. However, we observed a significant enrichment of Class 4/5 variants in exon 1, driven mainly by initiator codon variants, and a depletion of Class 4/5 variants in exon 5. By integrating published knowledge on molecular mechanisms, genetic variants, clinical progression, and therapeutic development, with a detailed analysis of ClinVar-annotated variants, this narrative review outlines the current understanding of -associated retinopathy and identifies key gaps that will need to be addressed for therapeutic development and clinical translation. : ClinicalTrials.gov: NCT06982417.

Human mutation 2026 PubMed
16 MYLK c.4079G>A, p.(Gly1360Asp) Variant Associated With Hereditary Thoracic Aortic Diseases and Early Onset Aortic Dissection. Virtanen M et al. 10.1111/ahg.70064
View abstract

AIMS: Thoracic aortic aneurysms and dissections are major causes of sudden cardiovascular death. We aimed to evaluate the clinical significance of the MYLK c.4079G>A, p.(Gly1360Asp) variant in Finnish families with heritable thoracic aortic disease (HTAD) and to assess evidence for a potential founder effect. METHODS: We evaluated the clinical significance and potential founder effect of the missense variant MYLK c.4079G>A, p.(Gly1360Asp) in Finnish families. Eight individuals from four unrelated Finnish families carrying the MYLK c.4079G>A heterozygous variant were recruited. Clinical histories, imaging data, and pedigrees were reviewed. Genetic testing included exome‑based gene panel sequencing or targeted familial variant testing. Variant classification followed the American College of Medical Genetics and Genomics 2015 guidelines. RESULTS: Thoracic aortic dilatation or aneurysm occurred in 6/8 carriers (75%), with a mean age at diagnosis of 45 years (range 34-67). Ascending aortic diameters ranged from 26-59 mm, most often measured at the aortic root. Aortic dissection occurred in 4/8 (50%) at a mean age of 46 years (range 34-68), including three early‑adult events. Extrathoracic arterial involvement (carotid) was observed in one variant‑positive individual. CONCLUSION: The MYLK c.4079G>A, p.(Gly1360Asp) variant was present in six affected individuals from four unrelated families and is enriched in the Finnish population, supporting a founder effect. The MYLK c.4079G>A, p.(Gly1360Asp) variant is associated with early‑adult‑onset, high‑penetrance thoracic aortic disease and substantial dissection risk, underscoring the need for vigilant surveillance and early intervention in affected individuals and at‑risk relatives.

Annals of human genetics 2026 Oct 18 PubMed
17 Prediabetes subtype-based stratification reveals distinct long-term risks for type 2 diabetes. Choe HJ et al. 10.1007/s00125-026-06866-4
View abstract

AIMS/HYPOTHESIS: Prediabetes is heterogeneous, with subtypes defined by impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or HbA, each with different risks of progression to type 2 diabetes. We compared progression across these subtypes, and evaluated the benefit of adding insulin secretion and sensitivity to risk stratification. METHODS: We analysed 7186 Korean adults aged 40-69 years from the community-based Korean Genome and Epidemiology Study, who were followed for up to 20 years with biennial (every 2 years) oral glucose tolerance tests and HbA. Prediabetes was classified as IFG, IGT or HbA-defined, and further stratified by insulinogenic index (IGI) and insulin sensitivity index (ISI). Cox regression was used to estimate diabetes risk, and multistate Markov models were used to assess annual transition probabilities and time spent in each state. RESULTS: Compared with normoglycaemia, the adjusted hazard ratios (aHRs) were 5.84 (95% CI 5.03, 6.79) for IFG, 4.60 (95% CI 4.17, 5.07) for IGT, and 4.68 (95% CI 4.22, 5.19) for HbA-defined prediabetes. The risk increased stepwise with the number of criteria met: the aHRs were 3.10 (95% CI 2.81, 3.41) for one criterion, 7.33 (95% CI 6.50, 8.28) for two criteria, and 15.3 (95% CI 12.2, 19.3) for all three. Markov models showed the shortest prediabetes duration (1.7 years) and lowest regression probability (5.4%) in those meeting all three criteria. Low IGI or ISI predicted higher diabetes risk, and dual impairment conferred greatest risk (aHR 4.06; 95% CI 3.37, 4.90). Even normoglycaemic individuals with low IGI or ISI had an elevated risk of diabetes compared to those with high IGI or ISI. CONCLUSIONS/INTERPRETATION: Diabetes progression differs based on both glycaemic subtype and physiological subtype. Integrating IGI and ISI with conventional definitions enhances risk stratification and may help to identify high-risk individuals for earlier targeted intervention.

Diabetologia 2026 Oct 17 PubMed
18 Metabolic health is a stronger determinant than obesity for cardiovascular disease incidence: a meta-analysis of longitudinal cohort studies. Ghorbani Z et al. 10.1038/s41366-026-02237-6
View abstract

Overweight and obesity are established risk factors for cardiovascular diseases (CVDs), yet heterogeneity in metabolic health among individuals with varied body mass index (BMI) complicates risk assessment. This systematic-review and meta-analysis of cohort studies investigated the risk of combined BMI-metabolic health phenotypes in relation to CVDs. PubMed and Scopus were searched up to January 2025. Metabolic phenotypes were defined as individuals with metabolically healthy normal weight (MHNW), metabolically healthy overweight (MHOW), metabolically healthy obesity (MHO), and their metabolically unhealthy counterparts, were analyzed for associations with CVD, coronary heart disease (CHD), myocardial infarction (MI), stroke, and heart failure (HF). Hazard ratios (HRs) and 95%confidence intervals (95% CIs) were pooled using random-effects models. Fifty-one publications (44 studies) were included. Compared with MHNW individuals, individuals with metabolically unhealthy obesity exhibited significantly higher risks across all cardiovascular outcomes with HRs of 2.10 (1.85-2.40) for CVD, 1.97 (1.71-2.27) for CHD, 2.20 (1.75-2.76) for MI, 1.55 (1.38-1.78) for stroke, and 2.05 (1.65-2.54) for HF. There was a positive dose-response relationship between both higher BMI and poor metabolic health and risk of CVD, CHD, MI, and HF incidence, however, associations for metabolically unhealthy normal weight subjects often exceeded that of metabolically healthy obese subjects. For stroke, poor metabolic health appears to be a primary determinant of risk. In conclusion, worsening metabolic health and higher BMI independently associated with increased CVD, CHD, MI, and HF risk, with their combination posing the greatest risk, while stroke risk was mainly associated with metabolic health.

International journal of obesity (2005) 2026 Oct 17 PubMed
19 Zyxin protects against hypertensive nephropathy by restraining FAK/Skp2-CDK8/YAP signaling in tubular epithelial cells. Huang W et al. 10.1007/s00011-026-02373-9
View abstract

BACKGROUND: Tubulointerstitial fibrosis and inflammation are hallmark pathological features of hypertensive nephropathy (HN), yet the underlying molecular mechanisms remain elusive. Zyxin, a focal adhesion protein, has been implicated in hypertension-related pathologies, but its specific role in HN-induced tubulointerstitial injury remains undefined. METHODS: An HN murine model was established via a multi‑hit DOCA/Ang II + uninephrectomy + high salt approach. Intrarenal zyxin was overexpressed using adeno-associated virus. In vitro, HK-2 cells were stimulated with Ang II, and zyxin levels were modulated via lentiviral transduction. Renal function, inflammation, and fibrosis were evaluated through biochemical assays and molecular signaling analysis. RESULTS: Zyxin was significantly downregulated in the renal tubules of HN mice and Ang II-treated HK-2 cells. Zyxin overexpression significantly improved renal function and attenuated tubulointerstitial injury, with a representative reduction of approximately 40% in the expression of fibrotic markers. These protective effects occurred independently of blood pressure changes. Mechanistically, zyxin reduction is linked to Ang II-induced calpain activation. The resulting zyxin depletion potentially disinhibits the FAK/Skp2 axis and enhances CDK8/YAP signaling, which may contribute to renal inflammation and interstitial fibrosis. CONCLUSIONS: These findings support a model in which zyxin acts as a protective factor in the renal tubules during HN, suggesting its potential as a novel therapeutic target.

Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2026 Oct 17 PubMed
20 Immune checkpoint inhibitor-associated myocarditis: clinical and mechanistic insights. Liu H et al. 10.1007/s00011-026-02397-1
View abstract

BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but can cause immune-related adverse events, including potentially severe cardiovascular toxicities. Although rare, immune checkpoint inhibitor-associated myocarditis (ICIM) can present early and may be rapidly fatal, posing a significant challenge at the crossroads of oncology, immunology, and cardiology. PURPOSE: This review synthesizes emerging clinical and experimental evidence to refine understanding of risk factors for immune checkpoint inhibitor-associated myocarditis and to outline a practical clinic-to-bench framework linking surveillance and diagnostic decision-making to pathogenic cellular programs. CONCLUSIONS: We highlight the cardiac immune microenvironment as a network of multicellular interactions in which cytotoxic T cells and inflammatory myeloid subsets engage with cardiomyocytes, endothelial cells, and fibroblasts through reinforcing feedback loops. Specifically, interferon-γ (IFN-γ)-driven myeloid activation and chemokine programs (CXCR3-CXCL9/10, CXCL16-CXCR6) coordinate immune cell trafficking and promote tissue injury, while stress-related cell death pathways can trigger innate immune sensing via the cGAS-STING axis. Current management remains centered on early recognition and corticosteroid-based immunosuppression, but emerging mechanistic insights reveal opportunities to improve therapy by targeting immune cell trafficking and inflammatory amplification pathways. Together, these advances support a more integrated cardio-oncology approach to ICIM, in which mechanistic insights inform risk stratification, earlier diagnosis, and the development of more precise immunomodulatory therapies.

Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2026 Oct 17 PubMed
21 Persistent hypertension and left ventricular remodeling after stenting for coarctation of the aorta: a single-center cohort study. Zhao K et al. 10.1038/s41371-026-01237-3
View abstract

Persistent hypertension (HTN) remains common after covered stent implantation for coarctation of the aorta (CoA). However, existing evidence is derived predominantly from surgical repair cohorts and cross-sectional echocardiography, leaving the individual trajectory of left ventricular (LV) remodeling after stenting poorly defined. We retrospectively studied 84 patients with complete persistent HTN status, and 75 patients with paired follow-up echocardiography for LV remodeling analyses. Multivariable logistic and linear regression were performed to identify factors associated with persistent HTN and follow-up LV mass index (LVMI) separately. Paired changes in LV hypertrophy (LVH) and LV geometry were assessed using McNemar and Stuart-Maxwell tests. Persistent HTN occurred in 46 of 84 patients (54.8%) at a median clinical follow-up of 9 years, and was associated with older age at repair and higher preoperative systolic blood pressure. Higher follow-up LVMI was associated with higher baseline LVMI, male sex and longer follow-up duration. At a median echocardiographic follow-up of 2 years, LVH prevalence decreased from 41.3-24.0%. This net decline masked bidirectional individual trajectories: 19 of 31 patients with baseline LVH (61.3%) no longer met LVH criteria, whereas 6 of 44 patients without baseline LVH (13.6%) developed new-onset LVH. Anatomical relief after CoA stenting therefore does not preclude ongoing myocardial burden, and patients developing new-onset LVH would not be identified by preoperative risk stratification alone. Serial echocardiographic assessment should complement long-term blood pressure surveillance, though these findings require validation in larger cohorts with standardized follow-up.

Journal of human hypertension 2026 Oct 17 PubMed
22 Single-cell RNA sequencing identifies a proinflammatory S100a8/a9(+) macrophage subset contributing to acute kidney injury. Ren T et al. 10.1007/s00011-026-02395-3
View abstract

OBJECTIVE: Macrophages represent a heterogeneous cell population in the kidney. However, macrophage subsets and their role in endotoxemia-induced acute kidney injury (AKI) remain elucidated. MATERIAL AND METHODS: Single-cell RNA sequencing was performed to identify macrophage subpopulations in mouse kidney following lipopolysaccharide (LPS) challenge. AKI was induced by LPS treatment or renal ischemia reperfusion injury in wild-type or S100a9 mice. Silencing or overexpression of S100a9 was carried out to assess its function and contribution to LPS-induced inflammation and AKI. In addition, bone marrow cells from S100a9 mice were injected into the recipient mice to determine the effect of S100a9 deletion in macrophage differentiation and renal inflammatory injury. RESULTS: By using single-cell RNA sequencing, we identified a unique S100a8/a9Ly6c proinflammatory macrophage subpopulation in mouse kidney following LPS challenge. LPS administration induced the infiltration of Ly6c macrophages into kidney tissues and significantly upregulated the expression of S100a8 and S100a9. S100a9 deletion downregulated S100a8 expression, decreased CD11bLy6c macrophages, and suppressed proinflammatory cytokine production in the kidney, attenuating LPS or ischemia reperfusion-induced renal inflammation and AKI. Bone marrow transplantation from S100a9 mice donors, but not from wild-type mice donors, reduced infiltration of CD11bLy6c macrophages and renal inflammatory injury. S100a8/a9 overexpression activated the nuclear factor-κB signaling pathway and promoted the production of proinflammatory cytokines in macrophages. CONCLUSIONS: S100a8/a9 plays a regulatory role in CD11bLy6c macrophage population differentiation, contributing to endotoxemia-induced AKI. S100a8/a9 blockade may be a novel therapeutic strategy for the prevention or attenuation of AKI.

Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2026 Oct 17 PubMed
23 Rapid Progression of Cardiac Allograft Vasculopathy With Sudden Cardiac Death Within the First Year of Heart Transplantation: A Case Report. Dix M et al. 10.1016/j.transproceed.2026.09.019
View abstract

Cardiac allograft vasculopathy (CAV) is a major cause of mortality and morbidity within the first 3 years of heart transplantation (HT). CAV results in progressive coronary artery stenosis and may lead to arrhythmias and sudden cardiac death. In some cases, sudden cardiac death represents the initial presentation of CAV, as cardiac denervation blunts anginal symptoms that otherwise could have preceded sudden cardiac death (SCD). Here, we describe the case of a 56-year-old man with non-ischemic cardiomyopathy. He underwent left ventricular assist device implantation followed by orthotopic HT. Five months after transplantation, he presented with atypical mid-sternal chest discomfort initially thought to be musculoskeletal in origin. Routine coronary angiography at 12 months revealed severe, diffuse 3-vessel disease consistent with International Society of Heart and Lung Transplantation (ISHLT) CAV-3, and cardiac MRI revealed full thickness delayed enhancement in the inferior wall consistent with infarction. Despite overall preserved left ventricular ejection fraction, he developed polymorphic ventricular tachycardia (VT) with an appropriate shock from a wearable cardioverter-defibrillator (WCD) and was transferred with an intra-aortic balloon pump to a larger transplant center and underwent another heart transplantation. This case highlights rapid CAV progression leading to infarction and arrhythmia despite preserved LVEF, emphasizing the need for enhanced screening with biomarkers and imaging as well as earlier consideration for device-based strategies to prevent sudden cardiac death in high-risk transplant recipients.

Transplantation proceedings 2026 Oct 17 PubMed
24 Echocardiographic estimates of pulmonary artery acceleration time and mortality risk in older adults. Nations JA et al. 10.1016/j.amjmed.2026.06.049
View abstract

BACKGROUND: Pulmonary artery acceleration time (PAAT) is an echocardiographic measure associated with pulmonary artery pressure. Although reduced PAAT has been linked to pulmonary hypertension and adverse outcomes in selected patient populations, less is known about its prognostic significance in community-dwelling older adults, which was the focus of the present study. METHODS: Using baseline echocardiographic PAAT measurements, we categorized 2758 participants in the Cardiovascular Health Study into PAAT >130 ms (N = 758), 100-130 ms (N = 1089), and <100 ms (N = 911). Cox regression models were used to estimate associations with mortality (reference, PAAT >130 ms), and restricted cubic spline analyses were used to assess nonlinearity of the associations (reference, PAAT 130 ms), during a median follow-up of 13.4 years. RESULTS: All-cause mortality occurred in 75.2%, 82.9%, and 85.5% of participants with PAAT >130 ms, 100-130 ms, and <100 ms, respectively. Corresponding age-sex-race-adjusted HRs (95% CIs) were 1.00, 1.11 (0.99-1.23) and 1.20 (1.08-1.34). Associations were attenuated primarily by adjustment for World Health Organization Group 2 (cardiac) but not Group 3 (pulmonary) pulmonary hypertension physiology and by adjustment for subclinical biomarkers and were no longer significant in fully adjusted models. Associations and attenuations were stronger for cardiovascular mortality than non-cardiovascular mortality. Restricted cubic spline analyses demonstrated no significant nonlinearity in age-sex-race-adjusted HRs for total mortality, which increased progressively at PAAT values below 130 ms. CONCLUSIONS: Lower PAAT is associated with higher risks of death in community-dwelling older adults. The association appears to be explained largely by cardiovascular disease and systemic health status rather than pulmonary disease alone. PAAT may serve as an integrated marker of cardiopulmonary and systemic vulnerability in older adults.

The American journal of medicine 2026 Oct 18 PubMed
25 CD4+ T Cell Activation and Peripheral Immune Cell Influx into the Brain Following Wildfire Smoke Exposure is Modulated by a Saturated Fat Diet. Baird B et al. 10.1016/j.neuro.2026.103589
View abstract

Over the past 40 years, wildfires across the United States have steadily increased, in terms of acreage burned. Smoke from wildfires can exacerbate several cardiovascular and respiratory diseases, with new studies highlighting potential sustained neurological outcomes. The purpose of this study was to delineate the role of peripheral immune populations in woodsmoke-induced neuroinflammation, the timeline of this response, and the impact of diet on each of these factors. Based on previous research on other pollutants and diet introduction, we included a highly saturated fatty acid (coconut oil) to represent the effects of a diet intervention that may modulate the severity and time course of peripheral immune infiltration. 8-week-old female C57BL/6 mice were exposed to either a sham filtered air or a woodsmoke exposure of a 0.5mg/m concentration every other day for 14 days, 4hr/day. Three time points were analyzed: 1-, 14-, and 28-days post exposure to woodsmoke to determine neuroinflammation at its peak and when it begins to resolve. At each time point, brains were queried by high dimensional flow cytometry analysis. Markers for peripheral immune infiltration included T cells (CD3, CD4), lymphocyte trafficking (LFA-1), resident immune cells (CD11b, ACSA-2) and other inflammation-dependent markers. Endothelial cell populations (CD31) and relevant adhesion molecules (VCAM-1, ICAM-1) were also analyzed. Results demonstrate a time and diet-dependent influx of CD4 T cells (Cd11b, CD3, CD4, RORγ, FOXP3, CD44), potentially to resolve neuroinflammation from woodsmoke inhalation. We also see a pattern of inflammation across several trafficking and adhesion markers, including LFA-1, VCAM-1 and ICAM-1, that peaks at 1 day after the last exposure (14 days after the initial insult). Conferred with these results are metabolomic changes in the brain including upregulated taurine and glycerolipid metabolism that is mainly tied to increased susceptibility to inflammatory phenotypes in the brain. Here, we demonstrate that woodsmoke inhalation can initiate the recruitment of peripheral immune populations and activation of endothelial cell markers within the brain. The presence of these cells implicates a larger, more persistent impact on the central nervous system following woodsmoke exposure.

Neurotoxicology 2026 Oct 17 PubMed
26 Hepatic ChREBP Drives Cardiac Remodeling via ApoM Non-transcriptional Repression Shuang Zhang et al. 10.1161/CIRCRESAHA.125.327537 Circulation Research 2026 Scholar
27 PERFORMANCE COMPARISON OF LOGISTIC REGRESSION, RANDOM FOREST, AND XGBOOST WITH SMOTE AND HYPERPARAMETER TUNING IN THE CLASSIFICATION OF ACUTE MYOCARDIAL INFARCTION Annisa Nur Rohmah et al. 10.21831/jktm.v12i2.28433 Jurnal Kajian dan Terapan Matematika 2026 Scholar
28 FGF-23, microRNA and phosphate binders intake: Is there a relationship? A. Rind et al. 10.21518/ms2026-177 Meditsinskiy sovet = Medical Council 2026 Scholar
DoctiPlus Health Insights are compiled weekly from public trial registries, FDA databases, and academic publishers. All figures reflect the seven-day window ending on the report date. Data is provisional and subject to registry updates.

Primary sources

  • ClinicalTrials.gov — public registry
  • openFDA — adverse events & recalls
  • PubMed / NCBI — research papers
  • Semantic Scholar — citations & papers

About this report

  • Category: Heart Disease & Cardiovascular
  • Week: October 12 – October 19, 2026
  • Drugs tracked: New Trials This Week, Recruiting Now, Countries
  • Generated: November 14, 2026 at 10:50 PM
© 2026 DoctiPlus Care Vol. 7 · No. 46 · November 14, 2026 — 30 —